Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8929 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8929 |
High Similarity |
NPD1613 |
Approved |
0.8859 |
High Similarity |
NPD1653 |
Approved |
0.8714 |
High Similarity |
NPD3027 |
Phase 3 |
0.8643 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8571 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8344 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.8282 |
Intermediate Similarity |
NPD7054 |
Approved |
0.8232 |
Intermediate Similarity |
NPD7472 |
Approved |
0.8221 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.82 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.8193 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.8143 |
Intermediate Similarity |
NPD1091 |
Approved |
0.8125 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8125 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.811 |
Intermediate Similarity |
NPD7228 |
Approved |
0.8072 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.8067 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8056 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.8038 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8038 |
Intermediate Similarity |
NPD37 |
Approved |
0.8025 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8024 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.8014 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8014 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.8 |
Intermediate Similarity |
NPD4966 |
Approved |
0.8 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7976 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.795 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7888 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7879 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7879 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7879 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7875 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7875 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7844 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7823 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7818 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7811 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.773 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7687 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7655 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7654 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7651 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7639 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7633 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7613 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7602 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7546 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7545 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7534 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7534 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7515 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7468 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7466 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7455 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7442 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7438 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7434 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7431 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7425 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7421 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7394 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7389 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7376 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7368 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7362 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7357 |
Intermediate Similarity |
NPD228 |
Approved |
0.7356 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7345 |
Intermediate Similarity |
NPD6843 |
Phase 3 |
0.7345 |
Intermediate Similarity |
NPD6841 |
Approved |
0.7345 |
Intermediate Similarity |
NPD6842 |
Approved |
0.7337 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.733 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD1512 |
Approved |
0.732 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.732 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7312 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7305 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7303 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7299 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.729 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.729 |
Intermediate Similarity |
NPD4536 |
Approved |
0.729 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7289 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7284 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7273 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7273 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7268 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7229 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7229 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7209 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7208 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7207 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7205 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7205 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7204 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7188 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7188 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7186 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7183 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7181 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.717 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7169 |
Intermediate Similarity |
NPD3382 |
Approved |
0.7169 |
Intermediate Similarity |
NPD3383 |
Approved |
0.7169 |
Intermediate Similarity |
NPD3384 |
Approved |
0.7162 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.716 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.716 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7152 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7152 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7152 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7152 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7134 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7134 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7134 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7127 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7126 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7126 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7107 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7092 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7092 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7091 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7091 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7089 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7089 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7089 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7083 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7081 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7079 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7079 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7079 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7076 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7071 |
Intermediate Similarity |
NPD290 |
Approved |
0.707 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7066 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7056 |
Intermediate Similarity |
NPD7906 |
Approved |
0.7055 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7051 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7044 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7044 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7027 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7027 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7025 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7025 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7022 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7022 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7019 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7019 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7019 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7019 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7013 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7006 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD968 |
Approved |
0.7 |
Intermediate Similarity |
NPD4663 |
Approved |
0.698 |
Remote Similarity |
NPD3496 |
Discontinued |
0.697 |
Remote Similarity |
NPD5403 |
Approved |
0.6962 |
Remote Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.6957 |
Remote Similarity |
NPD3060 |
Approved |
0.6954 |
Remote Similarity |
NPD2489 |
Approved |
0.6954 |
Remote Similarity |
NPD27 |
Approved |
0.6954 |
Remote Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.6943 |
Remote Similarity |
NPD5735 |
Approved |
0.6941 |
Remote Similarity |
NPD7768 |
Phase 2 |
0.6928 |
Remote Similarity |
NPD6584 |
Phase 3 |
0.6918 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6914 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6914 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6914 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.6913 |
Remote Similarity |
NPD6516 |
Phase 2 |
0.6913 |
Remote Similarity |
NPD5846 |
Approved |
0.6908 |
Remote Similarity |
NPD6696 |
Suspended |
0.6905 |
Remote Similarity |
NPD7411 |
Suspended |
0.6901 |
Remote Similarity |
NPD4055 |
Discovery |
0.6897 |
Remote Similarity |
NPD2970 |
Approved |
0.6897 |
Remote Similarity |
NPD2969 |
Approved |
0.6894 |
Remote Similarity |
NPD2424 |
Discontinued |
0.689 |
Remote Similarity |
NPD6799 |
Approved |
0.689 |
Remote Similarity |
NPD1774 |
Approved |
0.6882 |
Remote Similarity |
NPD2563 |
Approved |
0.6882 |
Remote Similarity |
NPD2560 |
Approved |
0.6879 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6879 |
Remote Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD2238 |
Phase 2 |
0.6875 |
Remote Similarity |
NPD2796 |
Approved |
0.6875 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6875 |
Remote Similarity |
NPD3454 |
Phase 3 |
0.6862 |
Remote Similarity |
NPD6776 |
Approved |
0.6862
|
Remote Similarity |
NPD6782 |
Approved |